Atrophic acne scar
Conditions
Interventions
Cold Lifting Treatment Group:The research plan involved 30 participants in cold lifting treatment. The treatment was conducted once every 6 weeks according to the cold lifting operation standards and
Sponsors
Shenzhen People’s Hospital (The First Affiliated Hospital, Southern University of Science and Technology;The Second Clinical Medical College,Jinan University)
Eligibility
Sex/Gender
All
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: (1) Facial atrophic acne scars, including ice-pick type, box-type and roller-type; (2) Age 18 to 40 years old; (3) No active facial inflammatory diseases; (4) No systemic diseases and/or diseases causing changes in skin thickness; (5) No history of photosensitivity; (6) No intake of photosensitive foods and/or exposure to sunlight within two weeks before treatment; (7) No anti-inflammatory treatment with glucocorticoids or other drugs within two weeks before treatment; (8) No facial photobiomodulation and/or mesoderm injection treatment within six months before treatment.
Exclusion criteria
Exclusion criteria: (1) Pregnancy period; (2) Pathological scar; (3) History of malignant tumor; (4) Patients with active infectious diseases, contagious diseases and compromised immune system; (5) Those with electronic devices such as pacemakers or automatic defibrillators implanted; (6) Patients with ear diseases such as tinnitus or otitis media; (7) Patients with foreign objects implanted at the treatment site; (8) Patients with a history of mental disorders and unable to cooperate with treatment; (9) Other general conditions unsuitable for participating in the study: Participated in any clinical trial within 3 months before screening; Unable to tolerate pain; Had a history of drug abuse or used drugs within 6 months before screening or within 3 months before screening; Had infectious diseases such as syphilis, AIDS, hepatitis B, etc. before screening; Pregnant or lactating subjects; Subjects with serious cardiovascular, gastrointestinal, respiratory, endocrine, kidney, liver diseases, or liver dysfunction, history of malignancy (diagnosed with malignancy within the past 5 years), central nervous system disorders, and mental disorders who cannot fully understand and cooperate with the treatment; Other combined diseases that the researcher considers may interfere with the study assessment, or the researcher considers that participating in this study may pose greater risks for the subjects; Subjects considered unsuitable for participating in this study by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The échelle d'évaluation clinique des cicatrices 'acné (ECCA) at the 24th week after the last treatment;The Quantitative Global Scarring Grading System score (quantitative GSS) indicator at the 24th week after the last treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical scoring scale for acne scars(ECCA) at the 12th and 18th weeks after the last treatment;The Quantitative Global Scarring Grading System score (quantitative GSS) indicator at the 12th and 18th weeks after the last treatment;The VISIA spectrometer is used to assess the red areas on the skin, pores, Propionibacterium acnes bacteria, etc.;Evaluate the skin using multi-angle photos taken by a 3D digital shaping scanner.;The skin thickness, density, elasticity, oxygen content and blood flow at the treatment site are measured using skin ultrasound technology.; | — |
Countries
China
Contacts
Public ContactJianglin Zhang
Shenzhen People’s Hospital (The First Affiliated Hospital, Southern University of Science and Technology;The Second Clinical Medical College,Jinan University)
Outcome results
None listed